Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome

Cancer

Volumn 80, Issue 7, 1997, Pages 1241-1249

  Saretzki, Gabriele ^a,d   Hoffmann, Uwe ^a   Röhlke, Peter ^b   Psille, Roland ^a   Gaigal, Thorwald ^a   Keller, Gisela ^c   Höfler, Heinz ^c   Löning, Thomas ^b   Petersen, Iver ^a   Dietel, Manfred ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Clinical outcome; Loss of heterozygosity; Ovarian tumor; Polymerase chain reaction

Indexed keywords

ADULT; AGED; ALLELISM; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 9844228503     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1241::AID-CNCR7>3.0.CO;2-N     Document Type: Article

References (61)

1. Dodson MK, Hartmann LK, Cliby WA, De Lacey KA, Keeney GL, Ritland SR, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 1993;53:4456-60.
2. Cliby W, Ritland S, Hartmann L, Dodson M, Hailing KC, Keeny G, et al. Human epithelial ovarian cancer allelotype. Cancer Res 1993;53:2393-8.
3. Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991;51:5118-22.
4. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994;69:429-38.
5. Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995;55:5133-9.
6. Li X, Lee NK, Ye Y-W, Waber PG, Schweitzer C, Cheng Q-C, et al. Allelic loss at chromosomes 3p, 8p, 13p, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 1994;86:1524-9.
7. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995;24:215-21.
8. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, et al. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992;51:862-8.
9. Harada Y, Katagiri T, Ito I, Akyama F, Sakamoto G, Kasumi F, et al. Genetic studies of 457 breast cancers: clinicopathologic parameters compared with genetic alterations. Cancer 1994; 74:2281-6.
10. Liu E, Nuzum C. Molecular sleuthing tracking ovarian cancer progression. J Natl Cancer Inst 1995;87:1099-101.
11. Bostwick DG, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian epithelial tumors of borderline malignancy: a clinical and pathologic study of 109 cases. Cancer 1986;58:2052-65.
12. Rice LW, Berkowitz RS, Mark SD, Yauner DL, Lage JL. Ovarian epithelial tumors of borderline malignancy. Gynecol Oncol 1990;39:195-8.
13. Padberg B-C, Arps H, Franke U, Thiedemann C, Rehpennung W, Stegner H-E, et al. DNA cytophotometry and prognosis in ovarian tumors of borderline malignancy. Cancer 1992;69:2510-4.
14. Mok SC-H, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
15. Tenierello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
16. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok S. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-51.
17. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:380-92.
18. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, et al p53 mutation in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunhistochemistry. Int J Cancer 1995;64:52-9.
19. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, et al p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-32.
20. Lee JH, Kang YS, Park SY, Kim BG, Lee ED, Lee KH, et al p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995;85:43-50.
21. Serov SF, Scully RE. Histological typing of ovarian tumors: an International Histological Classification of Tumors. No.9. Geneva: World Health Organization, 1973.
22. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1-7.
23. Wright DK, Manos MM. Sample preparation from paraffin-embedded tissue.In: Innis MA, Gelfand DH, Sninski JJ, Wight TJ, editors. PCR protocols. Academic Press, 1990:153-8.
24. Keller G, Rotter M, Vogelsang H, Bischoff P, Becker K, Mueller J, et al. Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract: relation to clinicopathological data and family history. Am J Pathol 1995;147:593-600.
25. Petersen I, Reichel MB, Dietel M. Use of non-radioactive detection in SSCP, direct DNA sequencing and LOH analysis. J Clin Pathol 1996;49:M118-M121.
26. Weber JL, May PE. Dinucleotide repeat polymorphism at the D2S71 locus. Nucleic Acids Res 1990;18:2203.
27. Koorey DJ, McCaughan GW, Trent RJ, Gallagher ND. Dinucleotide repeat polymorphism at the locus D5S134 linked to the adenomatous polyposis coli (APC) gene. Hum Mol Genet 1992;1:655.
28. Dixon J, Dixon MJ. Trinucleotide repeat polymorphism at the D5S373 locus. Hum Mol Genet 1993;2:829.
29. Orphanes V, McGomu G, Boyle JM, Santibanez-Koref M. Thirteen dinucleotide repeat polymorphisms on chromosome 6. Hum Mol Genet 1993;2:2196.
30. Fountain JW, Hudson TJ, Engelstein M, Housman DE, Dracopoli NC. Dinucleotide repeat polymorphism at the D9S126 locus (9p21). Hum Mol Genet 1993;2:823.
31. Telator M, Concannon P, Tolun A. Dinucleotide repeat polymorphism at the NCAM locus. Hum Mol Genet 1994;3:842.
32. Stack M, Crinchton D, Santibanez-Kore M. Two dinucleotide repeat polymorphisms at 17p13. Hum Mol Genet 1994;3: 1443.
33. Neuhausen SL, Swensen J, Miki Y, Liu Q, Travitigian S, Shattuck-Eidens D, et al. A P1-based physical map of the BRCA1 region from D17S766 to D17S78 containing the breast cancer susceptibility gene BRCAl. Hum Mol Genet 1994;3:1919-26.
34. Weber JL, May PE. Dinucleotide repeat polymorphism at the D18S134 locus. Nucleic Acids Res 1990;18:2201.
35. Sainz J, Nechiporuk A, Kim U-J, Simon MI, Pulst SM. CA repeat polymorphism at the D22S430 locus adjacent to NF2. Hum Mol Genet 1993;2:2203.
36. Sainz J, Rasmussen M, Nechiporuk A, Vissing H, Cheng X, Karenberg JR, et al. Dinucleotide repeat polymorphism at the D22S351 locus. Hum Mol Genet 1993;2:1749.
37. Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 1993;67:551-9.
38. Cooke IE, Shelling AN, Le Meuth VG, Charnock FML, Ganesan TS. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosomes Cancer 1996;15:223-33.
39. Rodabaugh KJ, Blanchard G, Welch WR, Bell DA, Berkowitz RS, Mok SC. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors. Cancer Res 1995;55:2169-72.
40. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T; Xynos FP, et al. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 1996;56:606-11.
41. Eccles DM, Russel SE, Haites NE, Atkinson R, Bell DW, Gruber L, et al. Early loss of heterozygosity on 17q in ovarian cancer. The Abe ovarian cancer genetics group. Oncogene 1992;7:2069-72.
42. Pieretti M, Powell D, Gallion HH, Case EA, Conway PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 1995;26:393-7.
43. Zheng J, Benedict WF, Xu H-J, Hu S-X, Kim TM, Velicescu M, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995;87:1146-53.
44. Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice JM, et al. Alteration of the p53 TSG occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994;85:1247-56.
45. Gallion HH, Pieretti M, De Priese PD, van Nagell JR. The molecular basis of ovarian cancer. Cancer 1995;76:1992-7.
46. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast ovarian carcinomas. Science 1994;266:120-2.
47. McManus DT, Murphy M, Arthur K, Hamilton PW, Russell SEH, Toner PG. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. J Pathol 1996;179:177-82.
48. McManus DT, Yap EPH, Maxwell P, Russel SEH, Toner PG, McGee GOD. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994;174:159-68.
49. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
50. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992;65:40-4.
51. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr., Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-50.
52. Allan GJ, Cottrell S, Trowsdale J, Foulkes WD. Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22. Hum Mutat 1994;3:283-91.
53. Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, et al. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alteration involving 9p, including CDKN2. Cancer Res 1995;55:2150-7.
54. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
55. Hahn SA, Schuttke M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rosenblum E, et al. DPC4, a candidate tumor suppressor gene gene at human chromosome 18q21.1. Science 1995;271:350-3.
56. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, et al. Mad-related genes in the human. Nat Genet 1996;13:247-9.
57. Arnold N, Hagele L, Walz L, Schemp W, Pfisterer J, Bauknecht T. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer 1996;16:46-54.
58. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 1995;64:434-40.
59. Kim TM, Benedict WF, Xu H-J, Hu S-X, Gosewehr J, Velicescu M, et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 1994;54:605-9.
60. Phillips N, Ziegler M, Saha B, Xynos F. Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer 1993; 54:85-91.
61. Gabra H, Watson JEV, Taylor KJ, Mackay J, Leonard RCF, Steel DJ, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996;56:950-4.